SciSparc's Recent Acquisition Agreement
SciSparc Ltd. (NASDAQ: SPRC), a clinical-stage pharmaceutical company focused on neurological therapies, has announced a significant move that promises to enhance its portfolio and expand its operational capabilities. The company entered into a binding asset and share purchase agreement, signaling a shift that could redefine its market presence.
Details of the Agreement
Under the terms of the agreement, SciSparc is set to acquire a controlling stake in Miza III Ventures Inc. (TSXV: MIZA), a company listed on the TSX Venture Exchange. This acquisition includes the transfer of SciSparc's advanced clinical-stage pharmaceutical portfolio, as well as a 51% equity interest in SciSparc Nutraceuticals Inc., with the total value of the assets estimated at around US$11.6 million.
Valuation and Shares
The entire enterprise of Miza is valued at approximately US$3.3 million, factoring in its cash position. Upon completion of the deal, SciSparc will be granted 63.3 million common shares of Miza, alongside up to 48 million contingent rights linked to specific milestones. This move is expected to provide SciSparc with a controlling interest ranging from 75% to 84% post-transaction.
Future Steps for Miza
Once the acquisition is finalized, Miza will rebrand itself as "NeuroThera Labs Inc." and launch operations within both the pharmaceutical and supplemental sectors. The TSXV has provisionally authorized the transaction, with formalities expected to conclude by late October 2025.
Funding and Support
As part of the strategic plan, SciSparc intends to inject CAD 1 million (approximately US$716 thousand) into Miza through an unsecured convertible note, demonstrating its commitment to the successful integration of the company. The note is set to mature in two years and will accrue interest at a simple rate of 7% annually, eventually allowing conversion into Miza shares.
Innovative Product Pipeline
SciSparc's current development pipeline showcases its commitment to tackling neurological disorders. It includes SCI-110, which is under a phase IIb trial for Tourette syndrome, and a completed phase II trial for Alzheimer's disease. Another promising candidate, SCI-210, is designed to aid children with autism and is expected to undergo a comprehensive trial in the near future.
About SciSparc Ltd.
SciSparc Ltd. is dedicated to developing innovative therapies targeting severe disorders, leveraging cannabinoid-based treatments. The firm's portfolio reflects a strong commitment to scientific excellence and the advancement of medications that address pressing health issues. They also hold a controlling interest in a subsidiary that markets hemp seed oil products on major e-commerce platforms.
Frequently Asked Questions
What is the primary goal of SciSparc's acquisition?
The acquisition aims to enhance SciSparc's pharmaceutical portfolio and expand its operational capabilities by gaining control over Miza III Ventures Inc.
When is the expected completion date of the acquisition?
The parties anticipate closing the Proposed Transaction on or around late October 2025.
What are the key products in SciSparc's pipeline?
The key products include SCI-110 for Tourette syndrome, SCI-110 for Alzheimer's disease, and SCI-210 for autism.
How will the acquisition impact SciSparc's market position?
Acquiring Miza is expected to strengthen SciSparc's market position by providing additional resources and expanding its reach in the pharmaceutical sector.
What financial support is SciSparc providing to Miza?
SciSparc plans to invest CAD 1 million via an unsecured convertible note to support Miza's operations post-acquisition.
